Note: This is a preliminary transcript and may contain inaccuracies. It will be updated with a final, fully-reviewed version soon.
VIMTA LABS LTD (NSE: VIMTALABS) Q4 2026 Earnings Call dated May. 06, 2026
Corporate Participants:
Siva Rama Krishna Kambhampati — Chief Financial Officer
Harita Vasireddi — Managing Director and Whole Time Director
Unidentified Speaker
Satya Neerukonda — Executive Director
Analysts:
Vishal Manchanda — Analyst
Unidentified Participant
Unidentified Participant
Unidentified Participant
Umesh Matkar — Analyst
Unidentified Participant
Presentation:
Operator
Ladies and gentlemen, good day and welcome to Wimta Labs Limited Q4FY26 earnings call hosted by Systematic Institutional Equities. As a reminder, all participant lines will be in the listen only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call please signal an operator by pressing Star then zero on a Touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Mr.
Visal Machanda from Systematic Institution Equities. Thank you. And over to you sir.
Vishal Manchanda — Analyst
Thank you. Nitesh. Good evening everyone. On behalf of Systematics Institutional Equities I welcome you to the Q4FY26 earnings call of IMTA Lab. We thank the Vimta management for giving us an opportunity to host the call. We have with us the senior management of the company represented by Ms. Haritha Vasiruddy, Managing Director, Mr. Sathya Sirnivas Nirukonda Executive Director, Mr. Shiva Ramakrishna, Chief Financial Officer and Ms. Sujani Vasi Reddy, Company Secretary. I now hand over the call to the company management for opening remarks.
Siva Rama Krishna Kambhampati — Chief Financial Officer
Thank you, Michal. Good afternoon and a warm welcome everyone to our Q4 and FY26 earnings call of Vimtel Apps Limited. Please note that the investor presentation and the financial results are available on the company website and the stock exchanges. Also, anything said on this call which reflects our outlook for the future or which could be construed as a forward looking statement must be reviewed in conjunction with the risks that the company faces. The conference call is being recorded and the transcript along with the audio of the same will be made available on the website of the company as well as on the stock exchanges.
Please also note that the audio of the conference call is the copyright material of Twinta Labs limit and cannot be copied, rebroadcasted or attributed in the press or media without specific and written consent of the company from the management. We have with us Ms. Haritha Vas Reddy, Managing Director, Mrs. Satya Sinivas Nirukonda, Executive Director. Myself Sivaram Krishna Kamapati, CFO and Ms. Sushini Vas Reddy, Company Secretary. Now I request Our Managing Director Ms. Haritha Vas Reddy to provide you with the updates for the quarter and year ended 31st March 26th.
Thank you. And over to you, Ma’.
Harita Vasireddi — Managing Director and Whole Time Director
Am. Thank you, Shiva. Good evening everyone. Thank you for joining us on this call today. FY26 has been a year of strong execution, resilience and strategic progress for Vimta Labs. As we reflect on the year, I’m pleased to say that we have continued to build on our core strengths while laying the foundation for the next phase of growth. Throughout FY26, WMTA has delivered consistent growth across its core service lines, supported by robust demand, disciplined execution and unwavering focus on quality.
Pharmaceutical research and testing services remained our largest contributor, driven by good demand from both domestic and international customers. Food testing also demonstrated good momentum while our electronics and electrical testing and environmental testing continued to scale in line with expectations. The broader environment continues to be favorable, driven by tightening quality norms, increasing regulatory scrutiny, innovation in pharmaceuticals and allied industries and an expanding wellness ecosystem.
As such in the life sciences. These trends reinforce the relevance of our services and strengthen our confidence in the long term outlook of the industry. One of WMTA’s defining strengths is its commitment to quality and compliance. During the year, we successfully underwent multiple regulatory and customer audits, reinforcing the trust that global customers place in our systems, science and people. These outcomes are a testament to the strength of our processes and the dedication of our team. FY26 also marked a strategic milestone with our entry into Biologics contract research and development services.
The first year, which is this year, FY27 will be about execution, learning and building credibility. Our focus is on delivering well for customers, earning their trust and establishing WIMTA as a reliable partner in this complex and evolving space. We believe the long term potential is significant, but we will approach this opportunity with characteristic discipline and patience. WIMPA continues to maintain very healthy EBITDA margins, clocking about 35.8% in FY26 which we believe are among the best in the industry even by global standards.
While there may be natural fluctuations due to capacity ramp ups, maintenance costs, people investments and of course now the geopolitical issues, our focus remains on sustaining margins in a stable and competitive range over the medium term. Our progress in FY26 would not have been possible without the dedication and and expertise of our people. While talent, availability and attrition remain industry wide challenges, we have successfully retained critical scientific and leadership talent which remains central to sustaining quality, innovation and growth.
As we look ahead, we remain confident the opportunities across pharmaceuticals, food testing, electronics are real and growing. At the same time, we remain mindful of the global uncertainties, cost pressures and competitive intensity. I would like to thank our teams, our customers, our partners and all our shareholders for their continued trust and support. We remain committed to building long term value through quality, consistency and thoughtful growth. Thank you for being with us and we look forward to continuing this journey together.
Siva Rama Krishna Kambhampati — Chief Financial Officer
Thank you Ms. Haritha Good evening everyone again and thank you for joining our Q4 and FY26 earning call. I’ll begin with an overview of our financial performance for the quarter and the year ended 31st March 26th. After that we’ll open the floor for any questions. Before we move into the financials, I’d like to highlight that the following the divestment of our diagnostic and pathological services business in 24 the figures for the previous period have been regrouped to ensure a like to like comparison with the current quarters.
I will start with the financial highlights for the quarter. Total income for Q4FY26 stood at 1120 million as compared to rupees 961 million in Q4FY25 up by almost 16.6 year on year with a quarter on quarter increase of 11.5% when compared to Q4FY25. The staggering growth was on account of our Food and Pharma division performing exceptionally well. EBITDA stood at 421 million in Q4FY26 as compared to 347 million in Q4FY25 up by almost 21.5% year on year. EBITDA margin for the quarter stood at 37.6% profit after tax in Q4 FY26 stood at 211 million rupees as compared to 183 million in FY25, a growth of 15.2% year on year.
PAC margins for the quarter stood at 18.9%. Basic EPS was at 4.7 rupees coming to yearly performance. Total income for FY26 was at 4163 million rupees as compared to 3482 million in FY25 up by 19.5% year on year. EBITDA for FY26 was 1489 million as compared to rupees12.62 million in FY25 a growth of 18% year on year. EBITDA margin for the year is at 35.8%. Act was at 775 million rupees as compared to 668 million in FY25 increased by 16.1% year on year. Fat margin was at 18.6%. Basic EPS for the full year was at 17.4 rupees per share.
On the balance sheet side we continue to have a net debt free balance sheet with the cash in Cash equivalents including bank balances close to 650 million rupees. With that we can now open the floor for any question and answers. Thank you.
Operator
Thank you very much. We will now begin the question answer session. Anyone who wishes to ask the question May Press Star N1 on the Touchstone telephone. If you wish to remove yourself from the question queue, you May Press Star N2. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. A reminder to all the participants. You May Press Star N1 to ask the question. Reminder to all participants that you May Press Star N1 to ask a question.
We have first question from the line of Shreya Chatterjee from Ageless Capital. Please go ahead.
Unidentified Speaker
Hello sir. Thank you for taking my question and congratulations on the results. My question would be that on your four verticals will it be possible to give out the margin profile of each of the verticals and like going into the future, what would be the highest driver of the like, which vertical will grow the highest? And if you could also give some update on your biologic vertical. Thank you.
Questions and Answers:
Harita Vasireddi
We don’t differentiate the margins between our service lines. It’s all treated as one service so that that information is not available. And going forward, 90% of our revenues are driven by research and testing services for pharmaceuticals and food. So this will continue. Both these service lines will continue to drive the growth of the organization and.
Unidentified Participant
Vertical. Yeah,
Harita Vasireddi
So we have put in place the processes, systems, equipment people to start working on contract research services for biologics and peptides development. So the machinery and people, infrastructure, systems, everything is ready.
Unidentified Participant
So when do you see this biologics to be a significant contributor to your revenue profile?
Harita Vasireddi
Maybe not in its maiden year, too soon to comment on that. But this year what we hope to do is build traction in the market on board at least a few good clients and deliver well.
Unidentified Participant
And if I may ask like if it’s possible to disclose how much of your like service profile or the contract profiles are FTE versus FSS for these four verticals.
Harita Vasireddi
FTEs are only in the pharma service lines. Food and other businesses don’t really have FTEs. And even on the pharma side it’s limited to analytical services as of now. So it’s not a major percentage.
Unidentified Participant
So FFS would be the major percentage?
Harita Vasireddi
Yes.
Unidentified Participant
Okay, thank you.
Operator
Reminder to all the participants that you may ask questions by pressing star N1. Reminder to all the participants that you May Press Star N1 to ask the question. The next question from the line of Yogesh Patil, individual investor, please go ahead.
Unidentified Participant
Thank you very much for giving me opportunity. I just want to know what are the growth drivers which you see which is panning out the next one or two years and how does the business visibility going forward in terms of maybe I’m not asking for any bigger hypothetical but in let’s take it on quarter, on quarter basis or month on month basis, how do you see that your long term strategy is aligned with the revenues and. And do you think the in current environment it does, it does have any kind of impact on current environment in terms of revenue booking or maybe deferment of client due to this US trade or maybe supply chain issues arises due to Iran US war, Is there any impact of any global environment point number one Second, growth drivers in near term and how do you see the visibility in near term in terms of when you talk to your clients or maybe new prospective lines?
That’s it for my.
Harita Vasireddi
The growth drivers for our industry, which we call contract research and testing have more or less been same during the last decade. The only thing is outsourcing, whether it is for testing or research, whether it is pharmaceuticals, nutraceuticals, medical devices or even for that matter electronics or food, the outsourcing is growing. So all these industries on their own globally are growing at the rate of anywhere between 7 to even 11 12%. So. So that itself provides an opportunity for all the players within the industry.
Further to that we have been dominantly playing with just a few markets. So our business development efforts are to go out overseas and gain more market share. So other than that there’s nothing that is significantly or drastically shifting in terms of growth drivers within these coming to business visibility. What we see for our food pharma and electronics and electronics testing is that it’s good visibility. These are going to be industries that will flourish in the future as well because some of them are essential.
And we see that more and more R and D spending is happening. The pipelines, especially for pharmaceutical are shifting more towards large molecules. So the innovation aspect is I think on the upward trend because the shift is from small molecules to large molecules. And we also see a lot of smaller companies coming into the space of R and D wherein even the large companies are collaborating with the smaller companies to strengthen their RD pipelines. So all in all, I think for pharma, food and electronics, good visibility coming to electronics.
I think India’s Atma Nirbhar initiative and the focus on indigenizing a lot of defense Tools and vehicles, whatever is high. And that calls for a lot of testing. And Hyderabad is a hub for defense OEMs. So I think we are in a good space for now. But even putting aside defense overall, the electronic industry, what we hear, what we see also happening on the ground level is that there is a lot more activity in terms of investments that is happening. The manufacturers who were also predominantly playing only in the domestic market, look now towards overseas markets to sell their products.
So all this is a healthy environment for a testing lab as a third party to verify safety, compliance and quality of the products. Coming to what our long term strategies are, they are perfectly I think aligned to how these industries are growing and the macro trends within the industry impact of war is there on us. The cost of some input materials, consumables have gone up slightly. There is a slightly longer lead time for us in supply chains. So there is some impact directly on us as a result of this war.
What will the future impact be is a wait and watch. We’ll have to see how things pan out for everybody. And coming to last year, yes, I think the pharmaceutical industry was under strain because of the tariffs imposed by us. I think these have now been reversed. So whatever small lull that we had observed last year, we are hoping that will quickly be reversed. At least on the tariff side of things.
Unidentified Participant
At least from environment point of view. It means global environment or maybe industry prospects outlook. The FY27 would be better than 26 do you think? Based on your client interaction or experience? Because more and more defense electronics and plus your pharmaceutical launches. I think I don’t know how which segments going to benefit us. But based on your interaction with clients. Because see all these are the very very high growth areas in terms of clients interest and visibility. Even from government point of view.
And you are in right spot, sweet spot, sorry. In terms of launching any products, CDMO and electronics and plus food is again a growing industry. So I just try to understand is is there any in terms of client deferment of new products or is there any competition or do you see in terms of structural growth? Let’s take it maybe FY27 to FY30 based on your clients interaction. It means the first is your client and second is sector and third is competition in terms of margins. How do you see going forward here
Harita Vasireddi
In a flourishing industry, in a growing industry, competition is always going to be there. And competition only intensifies because it’s a very good environment. Now coming to know in near term you’re talking 2027 to 2030. If we talk subtracting the situation geopolitical situation and also putting aside the sudden surprise tariffs that these base countries are imposing on each other now if you remove those factors I think now things should be good. Better than what we have seen now things should only become better.
But given the uncertainties. No. I can only comment when those things happen because it’s anybody’s guess.
Unidentified Participant
I completely agree. But your company is very difficult to try because in other sectors you can try export data or maybe certain IPM growth and all in our our kind of business very difficult to get any basically growth drivers or maybe because all these business are in B2B and all is not in public domain actually we can’t nobody can track it in terms of that. If you get some give some visibility let’s take it can our company can grow. Let’s take a 20 to 25% kind of cager of three to four years and maintaining the profit that is possible or it is a very optimistic scenario
Harita Vasireddi
Now it’s a stretch number but definitely doable. No. And that’s what we target each each year.
Unidentified Participant
Okay. Okay. And in terms of let’s take expertise any clients we are dealing so that client is coming to us or it means launching product. He also what I’m trying to understand is client is a price sensitive or not
Harita Vasireddi
For some services which are very routine low technology, low science, those kind of services price competition will always be there. But then there are some specialty services where the scientific input is very critical. So there I think Wimta has an edge. So it’s a mix basically especially on the pharma side. Food tends to be more and more leveled ground for everybody. But companies that move fast whenever there’s a regulation change there is some advantage that can be taken out of that and that Wymter has been quite good at that so far.
Unidentified Participant
We maintaining gross margin and the incremental profit could be driven by only revenue growth. Right?
Harita Vasireddi
Yeah. Margins I think we’re already doing well at EBITDA level. I would say you can expect a correction of 1, 2% depending on how things are panning out right now. Because if the input cost goes up there could be some impact for us there. And also manpower is something that continuously keeps on increasing but we try to offset with the top line growth. So we can expect some correction. But more or less I think it will be maintained.
Unidentified Participant
Okay. But it will be manageable or maybe it can be nullified due to revenue growth also.
Harita Vasireddi
Yes, yes.
Unidentified Participant
Thank you very much. Thank you and all the best.
Harita Vasireddi
Thank you.
Operator
Thank you. Reminder to all the participants that you may press star and one to ask a question. Reminder to all the participants that you may press star and one to ask a question. We have next question from the line of Mr. Vishal Manchanda from Systematic Institutional Equities. Sir, please go ahead.
Vishal Manchanda
Yeah. Hi, good evening everyone. On, on. In one of your slides on the presentation that you published, it says the pharma analytical testing industry is about $9.7 billion. So could you kind of give us a sense like considering this industry size we are pretty very small and but despite being small, we are meaningfully large in the Indian context. So just wanted to understand why is that so despite the industry being large, India, the Indian market seems to be much smaller. So where are the gaps?
Like where does is testing not happening enough in India? What could be that reason?
Harita Vasireddi
I wouldn’t say that testing is not happening in India because regulators such as US fda, EMA level the ground for everybody and India remains on the generic side one of the largest players in these markets. But having said that, the R and D side of things I think is on a much lower scale in India compared to these developed markets. So maybe that’s one of the main reasons and for my understanding now these are just the numbers that I know is by 2030 the Indian analytical testing market will be around approximately $300 million.
It’s really, really small compared to the global market. And the main reason why we will not be able to tap into all that big size global market is because this tends to be something that is outsourced to local players because it’s not worth shipping a sample overseas for simple analysis or a short term analysis only where the project is of higher value would the customer also benefit in going to a country like India which gives the advantage of both time price, you know. So I think these are the factors.
Vishal Manchanda
So in, in that would, if NCE RND picks up in India that would be a trigger for the, for the industry to become larger. So when.
Harita Vasireddi
Yeah, so when is the NCI
Vishal Manchanda
Mean new chemical entity R D?
Harita Vasireddi
Yes. Yeah. Possible more R and D definitely is more work on all sides of testing and research. Right. Not only for analytical but also for pre clinical, clinical research everywhere.
Vishal Manchanda
And like in your existing revenue would large part of, in your existing pharma analytic revenue would large part of that be driven by NDA filings in the U.S. Generic filings in the U.S. Or there is something else beyond the NDA filings that you support
Harita Vasireddi
Analytical testing? I think by and Large remains on the ND side. I would ask Srinivas to supplement if there is anything else here.
Satya Neerukonda
Yeah, mostly on the ANDA side and on for the product release. Sorry,
Vishal Manchanda
You said product release.
Satya Neerukonda
Other general product release which is already what you call approved in the market and if they are filing andas then to support their ANDA pipelines includes both approved products anda new products 505v2s NDAs there could be some part of NDA analysis which is also done majority towards the JEMEC 505B2 NDA and ANDA.
Vishal Manchanda
Okay, and one on the biosimilar business, biologics business that you’ve started. Would you only do contract research and manufacturing there or would you also do some off the shelf products which you can offload to some companies willing to do biosimilars in the like Biosimilars in the US like you kind of do the initial development on biosimilar and keep it ready and maybe someone wants to kind of leverage that. What is that? Also a strategy
Satya Neerukonda
To start with? It is mostly contract research. That’s what we are going to start. We are going to develop products for sponsors or clients. Maybe at the later stage but initially that’s the plan.
Vishal Manchanda
And have we signed clients yet on the biosimilars side?
Satya Neerukonda
We have good inquiries and we will be closing them soon. We have a good attraction from Europe, from India, a couple of them from us as well. We’re just finalizing the product and the modality.
Vishal Manchanda
Great, thank you. I’ll come back in with you. Thank you very much.
Operator
Thank you. Reminder to all the participants that you may be star N1 to ask a question. Reminder to all the participants that you may press STAR and one to ask a question. The next question is from the line of Rohan Shah from RS Investment. Please go ahead.
Unidentified Participant
Hello. Thanks for the opportunity ma’. Am. I want to understand what has led to the growth this quarter. Think we have achieved highest ever revenue. And do you think we’ll be able to keep the keep up with this momentum? Maybe 121,30 crore every quarter in the revenues.
Harita Vasireddi
Yes, that’s the intent to keep moving at this momentum. And the prime drivers for Q4’s good revenues are our pre clinical and also food has done well food testing because Q4 tends to be good quarter for food testing. So these were the main reasons why we could push. We could have done better because in some areas we did not see the kind of growth that we were expecting. But definitely the intent and effort will be towards maintaining this momentum.
Unidentified Participant
Okay, ma’, am. That’s helpful. Ma’, am, one more question. On the environmental testing front, how is the performance? And I understand we are only providing post project monitoring. So just wanted to get some color on that.
Harita Vasireddi
It’s a very tiny part of our work that we do at wmta. We have moved away from EIA which is Environmental Impact assessment and now sticking only to PPM which is post project monitoring. And in this transition where we were moving away from eia, getting into ppm, what we could do is just keep the revenues there next year. These years we will try to push up the revenue. But as such this is not a high focus area for the company. Because the growth opportunities are not that high in this segment.
Unidentified Participant
Got it, ma’. Am. Got it. How has food been this quarter? And has the war impacted in any way?
Harita Vasireddi
There have. There was an impact especially the last fortnight of March. Because we sell exporters and we also support import testing at the NFL in Navi Mumbai. So there was an impact in the last fortnight.
Unidentified Participant
Okay, ma’. Am. Understood. That’s helpful. Ma’, am, I have more question but I will join back in the queue. Thank you.
Harita Vasireddi
Sure.
Operator
A reminder to all the participants that you press star N1 to ask a question. A reminder to all the participants that you may press star N1 to ask a question. The next question from the line of Anjali Singh from Bansal family office. Please go ahead.
Unidentified Participant
Hello. Thanks for the opportunity. So my first question is on the export side. Could you please quantify what is the percentage of export revenue
Harita Vasireddi
In Q4? It has been around 38%.
Unidentified Participant
Okay. And one more question. Now that we have a new facility up and running. So what are the overall utilization levels?
Harita Vasireddi
Utilization will slowly pick up. Because you don’t build a facility wherein you are going to occupy it immediately. That’s not how you plan facilities. So utilization will pick up this year, a little more next year, more the following year. So that’s how it is done, infrastructure wise.
Unidentified Participant
Okay. Okay. One last question. So you have mentioned that new biologics contract research will come in from FY27. That is next quarter means. So how are we place at the moment and how are the efforts being put to bring in new projects for the company?
Harita Vasireddi
Some projects are under discussion like I was mentioning in my opening remarks. No. The people, systems, infrastructure, equipment. It’s all ready and we are discussing some projects. And we hope something will materialize soon.
Unidentified Participant
Okay. Okay. That’s all from my side. Thank you so much. All the best.
Operator
Thank you. Reminder to all the Participants that you press star N1 to ask a question. Reminder to all the participants that you may press star N1 to ask a question. Next question from the line of Umesh Matkar from Sushil Financial Services. Please go ahead.
Umesh Matkar
Yes, thank you for the opportunity, ma’. Am. I would like to know about the subsidiary that has been approved in us. So in which segment are we looking into and also what sort of investments are we going to incur for the US subsidiary?
Harita Vasireddi
The purpose of undertaking this is to be closer to our customers because we have a sizable population there and also to give them greater confidence. They are on their soil, so it gives greater confidence for them. So for as of now, that is the intent that we have. If something develops in the future beyond this, I will certainly come back to all of you.
Umesh Matkar
Okay. And does it give advantage to us in case of tariffs if we set up a subsidiary in us?
Siva Rama Krishna Kambhampati
No, not much. So there’s hardly any impact of tariffs on the services that we provide. As MD has just mentioned, this is the main purpose of opening the subsidiary there is to be closer to the customers.
Umesh Matkar
Right. And my last question is. Yeah, got it. Yeah. And my last question is with the new capacity that has gone up, come up, so what sort of revenue can we look into, say once it fully gets off, get utilized?
Harita Vasireddi
The idea is to. When we took up this project of expansion, the idea was to have a facility that can take care of our growth at least for the next four, five years. So I think we are good so far. We have moved into these facilities and we see growth happening as you have seen for the last financial year. And the idea is to keep on continuing this momentum.
Umesh Matkar
Okay, thank you very much and wish you all the best.
Harita Vasireddi
Thank you.
Operator
Thank you. Reminder to all the participants that you may press Star Event to ask a question. Reminder to all the participants that you may press start to ask a question. We have next question from the line of. From eny. Please go ahead, sir. As there is no response, we take the next question. We have next question from the line now. Mr. Rohan Shah from RS Investment. Please go ahead.
Unidentified Participant
Thanks. Thanks. How are the electronics and electrical testing scaling and what is their medium term potential?
Harita Vasireddi
Last year for us has not been very exciting. In this segment. We were hoping that we would pick up some more momentum here. But we had leadership challenges which are fixed now. Leadership challenges on both the technical and operational, sorry, operational and BD side. So this is fixed now. But despite those challenges, I think the team has progressed which is very encouraging for us. We have retained most of Our customers and the word of mouth is strong for us in this region. So now since that factor is addressed, we hope to see some strong moment coming here.
Unidentified Participant
Got it, ma’. Am. That’s helpful. Ma’. Am, Also, with a net debt free balance sheet and, you know, 650 plus million cash, how does management plan to deploy capital going forward?
Harita Vasireddi
Very good question. As of now, there are no firmed up thoughts on what we will do with this money. But it’s good to always have cash on hand, especially in these uncertain times. So for now, I have no specific information to share.
Unidentified Participant
Okay, I understand that. One more question if I may squeeze in. Are there any plans for acquisition capacity expansions or investing in any new service lines?
Harita Vasireddi
Like I said, nothing concrete as of now. But if something materializes, I’ll definitely come back to you.
Unidentified Participant
All right. How should investors think about margins in the biologics business compared to the core testing business?
Harita Vasireddi
Honestly now, we think the margin should be around this region. Our expectation is that it might be a percent or a few percent here and there. The reason why we say this is because the early projects may come more from domestic clients. And also the other aspect is the cost of input material is quite high here. But once we develop some traction here and we have a track record, successful products processes that we have developed under our belt, we can go overseas. And I think when we go overseas, the margins can be good.
Unidentified Participant
All right, ma’, am, that’s from my side. Thank you, ma’. Am.
Operator
Thank you. A reminder to all the participants that you may press star N1 to ask a question. A reminder to all the participants that you must press star N1 to ask a question. We have next question from the line now. Amita Modi, individual investor. Please go ahead,
Unidentified Participant
Ma’. Am. Our original plan was to clock 5F crore revenue annualized. So where we stand, is it possible to achieve it in FY27? And secondly, how confident we are to maintain our ebit margin over 35%?
Harita Vasireddi
Yes, we have had a very good CAGR during the last five to seven years. We want to maintain that cagr. And if you extrapolate that, then yes, the number that we are talking about is what we are also targeting. Our goal was to hit 500 by last year. But because of divestment of diagnostics, we said no, we will try and get to those run rates by Q4. But again, Q4, some headwinds in terms of external factors, I think we put a very strong effort and we would have really gone close to that number. But some things did not happen for us, which we were expecting.
But going forward we are hopeful. Very, very hopeful. But there are uncertainties in the environment now, as you all know.
Unidentified Participant
One more question. Is there any plan to raise money to ramp up the CapEx plan? Like we have cash of 65 million on hand, but is there any plan near term by way of right issue or some other way?
Harita Vasireddi
As of now we don’t need anything from that kind of a method. If there is, then we will definitely share that news.
Unidentified Participant
Okay, thank you.
Operator
Thank you. Reminder to all the participants that you may press star N1 to ask a question. As there are no further questions from the participants, I now hand conference over to management for closing comments.
Harita Vasireddi
Thank you to all the participants who took the time to join the call. I also wish to thank Systematics, especially Vishal, for being here and facilitating this call. Good day to all of you
Operator
On behalf of Systematic Institutional equities and Wimta Labs Ltd. That concludes this conference. Thank you for joining us and you may not distinct lines. Thank you.